

**SB 289 -1 STAFF MEASURE SUMMARY**

**Senate Committee On Health Care**

---

**Prepared By:** Daniel Dietz, LPRO Analyst

**Meeting Dates:** 3/6, 3/13

---

**WHAT THE MEASURE DOES:**

Directs the State Board of Pharmacy to study prescription drugs.

Fiscal impact: Minimal fiscal impact

Revenue impact: No revenue impact

**ISSUES DISCUSSED:**

**EFFECT OF AMENDMENT:**

-1

- Changes the requirement for the Department of Consumer and Business Services (DCBS) to produce a list of drugs exceeding certain price thresholds from each quarter to each year.
- Allows DCBS to identify up to nine drugs (instead of exactly nine) that may create affordability challenges.
- Directs the prescription Drug Advisory Board to report to the Health Care Cost Growth Target Program on the status of the generic drug market.

**BACKGROUND:**

Oregon's Prescription Drug Advisory Board (PDAB) was established within the Department of Consumer and Business Services (DCBS) by Senate Bill 844 (2021). In its [2024 Annual Report](#), the PDAB recommended several "cleanup" changes to its reporting requirements (2024 Annual Report at p. 11).

Senate Bill 289 allows the PDAB to report annually instead quarterly, to identify fewer than nine drugs for affordability review, and to include reporting on generic drugs in the affordability review report.